Kennedy Capital Management LLC Grows Position in Evolent Health, Inc. (NYSE:EVH)

Kennedy Capital Management LLC grew its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 40.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 365,186 shares of the technology company’s stock after purchasing an additional 105,748 shares during the period. Kennedy Capital Management LLC owned approximately 0.31% of Evolent Health worth $4,108,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Pilgrim Partners Asia Pte Ltd purchased a new stake in Evolent Health during the fourth quarter worth about $26,000. R Squared Ltd acquired a new stake in shares of Evolent Health during the 4th quarter valued at approximately $31,000. AlphaQuest LLC boosted its stake in shares of Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock worth $34,000 after acquiring an additional 3,031 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock worth $56,000 after acquiring an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new position in Evolent Health in the 4th quarter valued at approximately $61,000.

Wall Street Analysts Forecast Growth

EVH has been the topic of several research reports. JMP Securities reissued a “market outperform” rating and issued a $12.00 target price on shares of Evolent Health in a report on Friday, February 14th. Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of Evolent Health in a report on Friday, February 21st. Canaccord Genuity Group cut their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Stephens lowered their price target on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 21st. Finally, UBS Group dropped their price objective on Evolent Health from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, January 16th. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Evolent Health has an average rating of “Buy” and a consensus target price of $17.64.

Insider Activity at Evolent Health

In related news, CEO Seth Blackley purchased 55,225 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was acquired at an average price of $9.01 per share, with a total value of $497,577.25. Following the completion of the transaction, the chief executive officer now owns 762,217 shares of the company’s stock, valued at $6,867,575.17. This represents a 7.81 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Daniel Joseph Mccarthy bought 11,040 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was bought at an average price of $9.01 per share, for a total transaction of $99,470.40. Following the purchase, the president now owns 389,004 shares in the company, valued at approximately $3,504,926.04. This represents a 2.92 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 74,000 shares of company stock valued at $666,315. Corporate insiders own 1.60% of the company’s stock.

Evolent Health Stock Performance

Evolent Health stock opened at $10.02 on Friday. The stock’s 50-day moving average is $9.71 and its 200-day moving average is $13.85. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -12.22 and a beta of 1.20. Evolent Health, Inc. has a 12 month low of $8.35 and a 12 month high of $33.63. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). The company had revenue of $646.54 million during the quarter, compared to analysts’ expectations of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. Equities analysts anticipate that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.